Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aileron Therapeutics stock | $1

Own Aileron Therapeutics stock in just a few minutes.

Fact checked

Aileron Therapeutics, Inc is a biotechnology business based in the US. Aileron Therapeutics shares (ALRN) are listed on the NASDAQ and all prices are listed in US Dollars. Aileron Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of USD$46 million.

How to buy shares in Aileron Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aileron Therapeutics. Find the stock by name or ticker symbol: ALRN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aileron Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aileron Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aileron Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aileron Therapeutics share price

Use our graph to track the performance of ALRN stocks over time.

Aileron Therapeutics shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$1
52-week rangeUSD$0.25 - USD$2.47
50-day moving average USD$1.0513
200-day moving average USD$1.213
Wall St. target priceUSD$5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.605

Buy Aileron Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aileron Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aileron Therapeutics price performance over time

Historical closes compared with the close of $1 from 2020-12-09

1 week (2021-01-07) -18.70%
1 month (2020-12-17) -0.99%
3 months (2020-10-15) -48.45%
6 months (2020-07-15) 4.17%
1 year (2020-01-15) 22.03%
2 years (2019-01-15) -12.28%
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

Aileron Therapeutics financials

Gross profit TTM USD$-17,663,000
Return on assets TTM -52.62%
Return on equity TTM -132.65%
Profit margin 0%
Book value $0.312
Market capitalisation USD$46 million

TTM: trailing 12 months

Shorting Aileron Therapeutics shares

There are currently 1.2 million Aileron Therapeutics shares held short by investors – that's known as Aileron Therapeutics's "short interest". This figure is 6.6% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting Aileron Therapeutics shares can be evaluated.

Aileron Therapeutics's "short interest ratio" (SIR)

Aileron Therapeutics's "short interest ratio" (SIR) is the quantity of Aileron Therapeutics shares currently shorted divided by the average quantity of Aileron Therapeutics shares traded daily (recently around 738291.875). Aileron Therapeutics's SIR currently stands at 1.6. In other words for every 100,000 Aileron Therapeutics shares traded daily on the market, roughly 1600 shares are currently held short.

However Aileron Therapeutics's short interest can also be evaluated against the total number of Aileron Therapeutics shares, or, against the total number of tradable Aileron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aileron Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aileron Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0345% of the tradable shares (for every 100,000 tradable Aileron Therapeutics shares, roughly 35 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aileron Therapeutics.

Find out more about how you can short Aileron Therapeutics stock.

Aileron Therapeutics share dividends

We're not expecting Aileron Therapeutics to pay a dividend over the next 12 months.

Aileron Therapeutics share price volatility

Over the last 12 months, Aileron Therapeutics's shares have ranged in value from as little as $0.25 up to $2.47. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aileron Therapeutics's is 3.1398. This would suggest that Aileron Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aileron Therapeutics overview

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site